VEGF Inhibitors in Renal Cell Carcinoma

被引：3
|
作者：
Vachhani, Pankit [1 ]
George, Saby [1 ]
机构：
[1] Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
mTOR inhibitors; programmed death 1 inhibitors; RCC; renal cell carcinoma; VEGF inhibitors; VEGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arrival of targeted therapies-vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and programmed death 1 (PD-1) inhibitors has transformed the management of renal cell carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 year, these agents have nearly tripled overall survival and have raised hopes of a possible cure for advanced RCC. This review begins with a brief discussion of the seminal vonHippel-Lindau/hypoxia-inducible factor axis in RCC. It then discusses the pivotal trials that have investigated VEGF inhibitors in metastatic RCC, as well as in adjuvant and neoadjuvant settings. Finally, it addresses some practical considerations and future directions in the use of VEGF inhibitors in RCC.
引用
收藏
页码：1016 / 1028
页数：13
相关论文
共 50 条
  • [21] Emergence of HIF inhibitors in Renal Cell Carcinoma
    McDermott, David F.
    ONCOLOGY-NEW YORK, 2020, 34 (10): : 445 - 448
  • [22] Kinase inhibitors in the treatment of renal cell carcinoma
    Larkin, James M. G.
    Eisen, Tim
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (03) : 216 - 226
  • [23] Tyrosine kinase inhibitors in renal cell carcinoma
    Potti, A
    George, DJ
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6371S - 6376S
  • [24] Differentiating mTOR inhibitors in renal cell carcinoma
    Pal, Sumanta K.
    Quinn, David I.
    CANCER TREATMENT REVIEWS, 2013, 39 (07) : 709 - 719
  • [25] Metastatic Renal Cell Carcinoma Treated Sequentially with Multiple VEGF Receptor-targeted Inhibitors - A Case Report
    Linassier, Claude
    Carmier, Delphine
    Combe, Pierre
    D'Arcier, Benjamin Faivre
    Bruyere, Franck
    Narciso, Berangere
    ANTICANCER RESEARCH, 2012, 32 (02) : 697 - 700
  • [26] A clear cell renal carcinoma causing resistance to VEGF inhibitors in an age-related macular degeneration (AMD)?
    Vinagre, J.
    Falcao, M.
    Eloy, C.
    Soares, P.
    Lopes, J. M.
    VIRCHOWS ARCHIV, 2011, 459 : S49 - S49
  • [27] High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
    Fallara, Giuseppe
    Bandini, Marco
    Larcher, Alessandro
    Pederzoli, Filippo
    Karakiewicz, Pierre
    Tian, Zhe
    Briganti, Alberto
    Necchi, Andrea
    Salonia, Andrea
    Bertini, Roberto
    Montorsi, Francesco
    Bex, Axel
    Capitanio, Umberto
    CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
  • [28] Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
    Cho, Daniel C.
    ONCOTARGETS AND THERAPY, 2013, 6 : 679 - 684
  • [29] The place of VEGF inhibition in the current management of renal cell carcinoma
    Nathan, P
    Chao, D
    Brock, C
    Savage, P
    Harries, M
    Gore, M
    Eisen, T
    BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1217 - 1220
  • [30] Expression of VEGF in organ confined conventional renal cell carcinoma
    Mathers, ME
    Richards, J
    O'Donnell, M
    JOURNAL OF PATHOLOGY, 2001, 193 : 44A - 44A
12345